Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Eleview Versus Hetastarch as Injectate for EMR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Sex and age: men and women \> 18 years old~2. Subjects referred for EMR of polyps of size ≥11 mm~3. ASA score 1, 2 or 3.~4. Contraception: Women of childbearing potential must have a negative pregnancy test (one is provided as the standard of care) or sign a waiver. Post-menopausal women must have been in that status for at least 1 year (per standard of care).~5. Subject is willing and able to participate in the study procedures and to understand and sign the informed consent~Exclusion Criteria:~1. Age: Subjects is under 18 years old~2. Consent: Vulnerable subjects including those who are unable to consent~3. Pregnancy: Pregnant or breastfeeding women~4. ASA score \<3~5. Physical findings: Abnormal physical findings that may interfere with the study objectives~6. Study participation: Subjects currently participating in another clinical study or previously enrolled in another clinical study in the last 30 days~7. Excluded lesions:~   * Lesions less than 11 mm in largest dimension~  * Lesions involving the muscularis propria (T2 lesions)~  * Ulcerated depressed lesions (Paris type III) or pathology proven invasive carcinoma~  * Proven malignant disease locally advanced or with metastasis~  * Active inflammatory bowel disease lesion, e.g ulcerative colitis, Crohn's disease~  * Endoscopic appearance of invasive malignancy~8. Previous partial resection or attempted resection of the lesion~9. Allergy: Proven or potential allergic reaction to study products or history of anaphylaxis to drugs~10. Severe liver disease.~11. Known or suspected gastrointestinal obstruction or perforation, active diverticulitis, toxic megacolon,~12. Inflammatory bowel disease e.g ulcerative colitis or Crohn's disease~13. Hemostasis disorders (eg Von Willebrand disease, factor V Leiden thrombophilia or haemophilia), known clotting disorder (INR\>1.5).~14. Subject with any other current serious medical conditions that would increase the risks associated with taking part in the study.~15. Patients must be advised to stop anticoagulation medications prior to the procedure per local practice guidelines and should re-start as clinically indicated after the procedure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Eleview (Type: ACTIVE_COMPARATOR): This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
- Hetastarch (Type: ACTIVE_COMPARATOR): This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete